Demographic and clinical information on subjects
| Characteristics . | Distribution and range . | Testing variables . | P . | |
|---|---|---|---|---|
| Long-term allo HCT survivors . | Short-term allo HCT survivors* . | |||
| N | 25 | 32 | NA | |
| Time after transplantation | Median = 10 y; range =6-22 y | Median = 56 d; range = 7-98 d | NA | |
| Sex | Male = 15; female = 10 | Male = 14; female = 18 | Male, Female | .28 |
| Age at transplantation | Median = 42 y; range = 18-59 y | Median = 53 y; range = 19-65 y | ≤ 40 y, older | .29 |
| Age at time of sample collection | Median = 51 y; range = 31-68 y | Median = 53 y; range = 20-65 y | ≤ 40 y, older | .39 |
| Source of graft | Bone marrow = 18; blood stem cells = 7 | Blood stem cells = 30; cord blood = 2 | BM, PBSC | .001‖ |
| Disease | AML = 4; CML = 8; ALL = 6; CLL = 2; NHL = 3; MM = 1; SAA = 1 | AML = 13; CML/CMML = 2; ALL = 5; CLL/lymphoma = 11; MF = 1 | Meyloid, lymphoid | .92 |
| Type of transplantation | Related = 19; unrelated = 6 | Related = 16; unrelated = 16 | Related, unrelated | .06 |
| Conditioning† | Cy+TBI = 6, Cy+Bu = 7, Cy = 1, Flu+Bu = 9, VP16+TBI = 2 | Flu+Bu+TBI = 19, Flu+Bu = 12, VP16+TBI = 1 | TBI, no TBI | .07 |
| GVHD prophylaxis | CSA+MTX = 15, MTX+steroid = 2, CSA+MTX+ATG = 8 | CSA+MTX+ATG = 32 | ATG, no ATG | > .001‖ |
| Acute GVHD | Yes = 9; No = 16 | Yes = 13; No = 19 | Yes, No | −.78 |
| Chronic GVHD‡ | Yes = 18; No = 7 | NA | NA | |
| Oral chronic GVHD‡ | Yes = 14; No = 11 | NA | NA | |
| Time from oral cGVHD diagnosis to sampling | Median = 9 y; range = 4-21 y | NA | NA | |
| Active oral cGVHD at time of sampling | Yes = 2; N = 23 | NA | NA | |
| Patients on immunosuppression§ at time of sampling | Yes = 2; No = 23 | |||
| Characteristics . | Distribution and range . | Testing variables . | P . | |
|---|---|---|---|---|
| Long-term allo HCT survivors . | Short-term allo HCT survivors* . | |||
| N | 25 | 32 | NA | |
| Time after transplantation | Median = 10 y; range =6-22 y | Median = 56 d; range = 7-98 d | NA | |
| Sex | Male = 15; female = 10 | Male = 14; female = 18 | Male, Female | .28 |
| Age at transplantation | Median = 42 y; range = 18-59 y | Median = 53 y; range = 19-65 y | ≤ 40 y, older | .29 |
| Age at time of sample collection | Median = 51 y; range = 31-68 y | Median = 53 y; range = 20-65 y | ≤ 40 y, older | .39 |
| Source of graft | Bone marrow = 18; blood stem cells = 7 | Blood stem cells = 30; cord blood = 2 | BM, PBSC | .001‖ |
| Disease | AML = 4; CML = 8; ALL = 6; CLL = 2; NHL = 3; MM = 1; SAA = 1 | AML = 13; CML/CMML = 2; ALL = 5; CLL/lymphoma = 11; MF = 1 | Meyloid, lymphoid | .92 |
| Type of transplantation | Related = 19; unrelated = 6 | Related = 16; unrelated = 16 | Related, unrelated | .06 |
| Conditioning† | Cy+TBI = 6, Cy+Bu = 7, Cy = 1, Flu+Bu = 9, VP16+TBI = 2 | Flu+Bu+TBI = 19, Flu+Bu = 12, VP16+TBI = 1 | TBI, no TBI | .07 |
| GVHD prophylaxis | CSA+MTX = 15, MTX+steroid = 2, CSA+MTX+ATG = 8 | CSA+MTX+ATG = 32 | ATG, no ATG | > .001‖ |
| Acute GVHD | Yes = 9; No = 16 | Yes = 13; No = 19 | Yes, No | −.78 |
| Chronic GVHD‡ | Yes = 18; No = 7 | NA | NA | |
| Oral chronic GVHD‡ | Yes = 14; No = 11 | NA | NA | |
| Time from oral cGVHD diagnosis to sampling | Median = 9 y; range = 4-21 y | NA | NA | |
| Active oral cGVHD at time of sampling | Yes = 2; N = 23 | NA | NA | |
| Patients on immunosuppression§ at time of sampling | Yes = 2; No = 23 | |||
| Controls: autologous HCT survivors (controls for alloreactive milieu and effect of chemotherapy) . | |
|---|---|
| Characteristics . | Distribution and range . |
| N | 11 |
| Sex | Male = 7; female = 4 |
| Age at transplantation | Median = 54 y; range = 28-63 y |
| Age at time of sample collection | Median = 57 y; range = 50-68 y |
| Time after transplantation | Median = 5 y; range = 3 mo-8 y |
| Source of graft | All blood stem cells |
| Disease | Lymphoma = 10; amyloidosis = 1 |
| Conditioning* | BEAM = 7, Flu+Bu = 2, Mel+TBI = 1, Mel = 1 |
| Controls: autologous HCT survivors (controls for alloreactive milieu and effect of chemotherapy) . | |
|---|---|
| Characteristics . | Distribution and range . |
| N | 11 |
| Sex | Male = 7; female = 4 |
| Age at transplantation | Median = 54 y; range = 28-63 y |
| Age at time of sample collection | Median = 57 y; range = 50-68 y |
| Time after transplantation | Median = 5 y; range = 3 mo-8 y |
| Source of graft | All blood stem cells |
| Disease | Lymphoma = 10; amyloidosis = 1 |
| Conditioning* | BEAM = 7, Flu+Bu = 2, Mel+TBI = 1, Mel = 1 |
| Controls: chemotherapy recipients without HCT (controls for effect of chemotherapy) . | |
|---|---|
| N | 9 |
| Sex | Male = 2; female = 7 |
| Age at time of sample collection | Median = 52 y; range = 31-60 y |
| Time before transplantation | Median = 11 d; range = day 3-36 |
| Disease, stage | AML in 1st remission = 3; AML in/beyond 2nd remission = 4; CLL/lymphoma in/beyond 2nd remission = 2 |
| Controls: healthy controls | |
| N | 27 |
| Sex | Male = 10; female = 17 |
| Age at time of sample collection | Median = 38 y; range = 18-54 y |
| Controls: chemotherapy recipients without HCT (controls for effect of chemotherapy) . | |
|---|---|
| N | 9 |
| Sex | Male = 2; female = 7 |
| Age at time of sample collection | Median = 52 y; range = 31-60 y |
| Time before transplantation | Median = 11 d; range = day 3-36 |
| Disease, stage | AML in 1st remission = 3; AML in/beyond 2nd remission = 4; CLL/lymphoma in/beyond 2nd remission = 2 |
| Controls: healthy controls | |
| N | 27 |
| Sex | Male = 10; female = 17 |
| Age at time of sample collection | Median = 38 y; range = 18-54 y |
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease; AML, acute myeloid leukemia; Allo, allogeneic HCT; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; MF, myelofibrosis; BEAM, BCNU+etoposide+cytarabine+melphalan; Flu, fludarabine; Bu, busulfan; TBI, total body irradiation; Cy, cyclophosphamide; VP16, etoposide; Mel, mephalan; CSA, cyclosporine A (given for the first 3-6 months after transplantation, longer in case of chronic GVHD); MTX, methotrexate (given on days 1, 3, 6, 11); ATG, antithymocyte globulin (given on days −2, −1, 0); BM, bone marrow; and PBSC, peripheral blood stem cells (filgrastim-mobilized).
Controls for short-term effect of MTX or CSA.
Myeloablative in all patients, except possibly the one patient with severe aplastic anemia who received 200 mg/kg cyclophosphamide.
At any time between transplant and sample collection. In most patients, cGVHD was inactive at the time of sample collection.
Mycophenolate mofetil.
Significant P value.